My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Incannex Healthcare Inc. - Common Stock (NQ:IXHL)

3.767 -0.053 (-1.39%)

Streaming Delayed Price Updated: 2:15 PM EDT, Jun 12, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incannex Healthcare Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

March 15, 2023

Via Benzinga

Incannex Healthcare Has World's Largest Pipeline Of Psychedelic Products ↗

March 14, 2023

Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies.

Via Talk Markets

All 5 Cannabis Categories Down Last Week; Only 1 Is UP YTD ↗

March 12, 2023

The 5 categories in the cannabis sector perform quite differently from each other. Only 1 is up YTD.

Via Talk Markets

Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More ↗

March 07, 2023

Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been...

Via Benzinga

Here Are The Year's Highest Priced Psychedelics Stocks In US Markets ↗

March 06, 2023

After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on.

Via Benzinga

Incannex to work with Catalent to produce psilocybin for clinical and potentially commercial use

March 03, 2023

Incannex to work with Catalent to produce psilocybin for clinical and potentially commercial use

Via News Direct

Incannex to work with Catalent to produce psilocybin for clinical and potentially commercial use

March 03, 2023

Incannex Healthcare Ltd (ASX:IHL NASDAQ:IXHL) CEO and MD Joel Latham sits down with Proactive to talk about the development and manufacturing deal it has struck with pharma giant Catalent to produce...

Via TheNewswire.com

Incannex Engages Catalent For Development And Manufacture Of Psilocybin Drug For Clinical Trials ↗

March 03, 2023

Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL), a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic medicine therapies for unmet medical needs, has...

Via Benzinga

Incannex Healthcare kicks off Phase 2 rheumatoid arthritis trial

February 28, 2023

Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) CEO Joel Latham tells Proactive the company has begun a Phase 2 clinical trial, testing the safety and efficacy of its IHL-657A drug candidate in patients...

Via TheNewswire.com

Incannex Healthcare kicks off Phase 2 rheumatoid arthritis trial

February 28, 2023

Incannex Healthcare kicks off Phase 2 rheumatoid arthritis trial

Via News Direct

Incannex Starts Phase 2 Clinical Trial Of CBD-Based Drug For Use In Treatment Of Rheumatoid Arthritis ↗

February 28, 2023

Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has commenced a phase 2 clinical trial to assess the safety and efficacy of its proprietary anti-inflammatory combination drug IHL-675A in patients...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

January 25, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

January 25, 2023

Via Benzinga

Why eHealth Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket ↗

January 25, 2023

Gainers Inpixon (NASDAQ: INPX) shares rose 41% to $2.20 in pre-market trading after gaining 6% on Tuesday. Inpixon, last month, secured a purchase order valued at over $1m for its RTLS products from a...

Via Benzinga

Australian Psychedelics: Phase 2 Trial On Psilocybin For Anxiety Will Soon Share Results ↗

January 18, 2023

Australian biopharma company developing therapeutic cannabinoid products and psychedelic medicines Incannex Healthcare (NASDAQ:

Via Benzinga

Psyched: Psychedelic Therapy In The Workplace, UCL's Brain Imaging Study, COMPASS Trials And More ↗

December 13, 2022

Psychedelic Therapy Now Available As Workplace Benefit, Free Month For Laid-Off Tech Workers

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 08, 2022

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

December 08, 2022

We're starting off the day with a look at the biggest pre-market stock movers that traders will want to watch on Thursday!

Via InvestorPlace

Incannex Files A Provisional Patent Application Of Its THC-Based IHL-42X For The Treatment Of Obstructive Sleep Apnea ↗

December 06, 2022

Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL), announced the filing of a provisional patent application directed to the use of IHL-42X for the treatment of obstructive sleep apnea (‘OSA’).

Via Benzinga

Eurofins To Produce Incannex' 2 CBD Medicated Chews For Treatment Of Nicotine And Opioid Addiction Disorders ↗

November 28, 2022

Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has engaged multinational contract development and manufacturing organization Eurofins Scientific (OTCPK:ERFSF) to manufacture Incannex’s two...

Via Benzinga

Incannex Initiates BA/BE Clinical Trial Evaluating IHL-42X In Obstructive Sleep Apnoea ↗

November 17, 2022

Cannabis and psychedelics-focused Pharma company Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL) initiated a BA/BE study and is targeting submission of an IND application with the FDA in Q1...

Via Benzinga

A Global List Of Cannabis Operators And Executives To Keep An Eye On In 2022 And Beyond ↗

November 09, 2022

Less than 30 years after Israel became the first nation in the world to allow its citizens to use cannabis for medical purposes, the medical and adult-use cannabis markets have spread across the globe...

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

November 04, 2022

Gainers Incannex Healthcare (NASDAQ:IXHL) shares moved upwards by 30.7% to $5.19 during Friday's pre-market session. The market value of their outstanding shares is at $316.2 million.

Via Benzinga

Australian Psychedelics: Incannex Business & Financials, New Research Center For Mushrooms & Eating Disorders ↗

October 28, 2022

Clinical-stage biopharma company Incannex Healthcare Ltd. (NASDAQ: IXHL) shared its quarterly activities report and appendix 4C for the period ended 30 September 2022, noticeably applying for several...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

October 13, 2022

Good morning, investor! We're starting off Thursday with a breakdown of the biggest pre-market stock movers this morning!

Via InvestorPlace

Unrivaled Brands & Other Cannabis Operators Just Made Some Key Executive Changes You Should Know About ↗

August 19, 2022

As Benzinga Cannabis Capital Conference returns on September 13-14 to Chicago, gathering top CEOs, investors and leaders in the industry, let's scroll through the latest leadership changes within the...

Via Benzinga

Icannex Taps Ex Pfizer, FDA & Regulatory Affairs Expert ↗

August 17, 2022

Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) appointed pharmaceutical executive Robert B. Clark to the board of directors.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 22, 2022

Via Benzinga

Incannex Approved To Commence Phase 1 Clinical Trial Of CBD Based Anti-Inflammatory Drug ↗

July 21, 2022

Incannex Healthcare Limited (NASDAQ: IXHL) (ASX:IHL) has received approval from the Bellberry Human Research Ethics Committee ('HREC') for a phase 1 clinical trial investigating its proprietary...

Via Benzinga

Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday ↗

August 08, 2022

Gainers

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.